







Rates of Melioidosis in High-Risk
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Hospital, Tiwi, Darwin, Northern Territory, AustraliaIntroduction: Melioidosis causes sepsis and death in the Top End of Northern Australia during the
monsoonal wet season. Dialysis-dependent adults suffer higher melioidosis rates compared to low rates
among renal transplant patients who routinely receive trimethoprimþsulfamethoxazole prophylaxis.
Methods: We performed a prospective interventional study to determine the efficacy and safety of daily
trimethoprimþsulfamethoxazole prophylaxis in hemodialysis patients during the wet season, from 1
November 2014 to 30 April 2015. Hemodialysis (for $ 3 months) patients $ 18 years of age were offered
treatment. A total of 269 patients on hemodialysis were eligible. Eight of the 269 patients (3%) were
excluded from the analysis for being on melioidosis treatment. In all, 169 of 261 patients (64.8%) received
the prophylaxis, and 92 of 261 patients (35.2%) did not, because of allergy history (n ¼ 10), remoteness and
logistical reasons (n ¼ 60), poor dialysis attendance (n ¼ 11), and refusal (n ¼ 11). We monitored for clinical
side effects 3 times weekly and neutropenia, thrombocytopenia, and liver function monthly throughout
treatment and for 2 months posttreatment.
Results: In all, 169 of 261 patients (64.8%) received the prophylaxis. There was no age (years) difference by
group (prophylaxis vs. nonprophylaxis, 54.7 [11.3] vs. 54.3 [11.2] [P ¼ 0.751]). Sixteen of 261 patients (6%)
had melioidosis. The event frequency was 0% (0/169, prophylaxis, vs. 17.4% [16/92, nonprophylaxis],
P < 0.001). Higher thrombocytopenia and neutropenia rates were noted in the prophylaxis group. These
did not warrant treatment stoppage. There was no difference in liver function. Three patients (1.8%)
withdrew from the treatment because of side effects.
Conclusion: Daily dosing was effective and safe. Posthemodialysis dosing in the subsequent seasons was
effective and safer. We recommend this approach in melioidosis-prevalent regions.
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elioidosis causes severe sepsis and death in the
Top End of Northern Australia during the
monsoonal wet season.1 The wet season (melioidosis
season) is defined to capture the seasonal presentation
in the tropical wet season (November to April),2 with
average monthly rainfalls of 100 to 500 mm in the 6
months (Figures 1 and Supplementary Figure S1) andspondence: Sandawana William Majoni, Department of
ology, Division of Medicine, Royal Darwin Hospital, P.O. Box
, Casuarina, Darwin, Northern Territory, Australia. E-mail:
wanaw@aol.com
ved 4 May 2017; revised 12 September 2017; accepted 12
mber 2017; published online 19 September 2017high humidity of > 80%.3 Melioidosis is caused by the
saprophytic Gram-negative bacterium and Tier 1 select
agent Burkholderia pseudomallei, which naturally occur
in tropical soil and water.4 Burkholderia pseudomallei is
widespread in Northern Australia and Southeast
Asia and is increasingly recognized as being endemic
in other tropical regions globally.1,4–6 The Darwin
Prospective Melioidosis Study (DPMS) is a
long-running, large, prospective observational study
started in October 1989 that aims to understand the
clinical and microbiological aspects of melioidosis in
the Top End of the Northern Territory (NT), and to use
this information to lessen the burden of the disease
through earlier diagnosis and improved treatment. TheKidney International Reports (2018) 3, 160–167
Figure 1. Correlation between cases of melioidosis managed at
Royal Darwin Hospital in 2009–2010 and rainfall at Darwin airport.
Reproduced with permission from Parameswaran U, Baird RW,
Ward LM, et al. Melioidosis at Royal Darwin Hospital in the big
2009–2010 wet season: comparison with the preceding 20 years.
Med J Aust. 2012;196:345–348. Copyright ª 2012 The Medical
Journal of Australia.
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Top End of the NT since 1 October 1989,7,8 with
around 85% of cases occurring during the tropical wet
season (November to April)2 (Figure 1).
Chronic kidney disease (CKD) is an independent risk
factor for melioidosis, and CKD is associated with a
higher mortality rate whenever melioidosis occurs.9,10
Other factors associated with high risk for melioidosis
include diabetes mellitus, hazardous alcohol use,
chronic lung disease, rheumatic heart disease and
cardiac failure, and immune-suppressive medications,
most notably the use of corticosteroids. Age and
indigenous ethnicity are also independent predictors
for melioidosis. These factors are also common among
adult patients dependent on dialysis in this region.11 In
our region, we have previously reported staggering
higher incidence rates of melioidosis among
adults dependent on dialysis than among those
without dialysis-dependent CKD (988.8/100,000 vs.
24.0/100,000 patient-years), equating to a crude relative
risk for melioidosis among adults dependent on dialysis
of 38.4 (95% confidence interval [CI] ¼ 25.7–57.5).11
As observed in some previouswet seasons, during the
2011 to 2012 wet season, we observed a higher
frequency of melioidosis among the dialysis cohort.12
Rates of melioidosis are lower among our renal trans-
plant cohort. Our routine practice to specifically miti-
gate wet seasonassociated melioidosis for the renal
transplant and immunosuppressed cohort includes
consideration of trimethoprimþsulfamethoxazole
(TMPþSMX) prophylaxis treatment, at a dose higher
than usually used for Pneumocystis jirovecii pneumonia
(PJP) prophylaxis.13 Pharmacodynamic and pharmaco-
kinetic studies of TMPþSMX for the treatment of
Kidney International Reports (2018) 3, 160–167melioidosis indicate that high doses of oral TMPþSMX
are required for eradication after an initial intensive
treatment with i.v. ceftazidime or meropenem.10,14–18
There are no published data on the prophylactic use of
TMPþSMX (or any other antibiotics) to reduce melioi-
dosis in high-risk groups, although TMPþSMX has
been used as postexposure prophylaxis for Burkholderia
pseudomallei infection among laboratory staff.19 There-
fore, following the increase in both the number of
melioidosis cases observed in the 2011 to 2012 wet
season, and the concomitant increase in the size of the
prevalent dialysis patient cohort, we undertook a
prospective open-label intervention by implementing a
prophylaxis guideline for hemodialysis patients in the
Top End of theNorthern Territory over thewet season (1
November 2014 to 30 April 2015), using oral trimetho-
primþsulfamethoxazole (TMPþSMX), 160/800 mg
daily.
The aim of this study was to determine the efficacy
and safety of prophylaxis with daily TMPþSMX for
melioidosis in hemodialysis patients from the Top End
of Northern Australia during the wet season from 1
November 2014 to 30 April 2015.
MATERIALS AND METHODS
Study Design
The study was a prospective, open-label, interventional
study carried out as part of the larger Darwin Pro-
spective Melioidosis Study, which documents all cases
of melioidosis and treatment in the Top End of the
Northern Territory.20
Study Population
All patients $18 years of age who had been on main-
tenance hemodialysis for $3 months were offered the
prophylactic treatment. All eligible hemodialysis
patients throughout the Top End received daily
TMPþSMX, excluding persons with known hyper-
sensitivity to trimethoprim and/or sulfamethoxazole,
lipoamides, or any other ingredients in the formula-
tions of the tablets, severe hepatic failure, marked
liver parenchymal damage or jaundice, or serious
hematological disorders (thrombocytopenia < 80,000
platelets/ml, leukopoenia < 3.5  109/l (neutrophil
count < 2.7  109), and porphyria, and any other
contraindications to TMPþSMX. Those who declined
the treatment were also excluded from the prophylaxis
treatment. The cohort could therefore be described
categorically as those who received the intervention
and a control group of those who were ineligible for the
intervention (or TMPþSMX-group [prophylaxis] vs.
nonprophylaxis group).
All patients received the usual wet season advice on
melioidosis prevention.14161
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Patients’ ethnicity was entered as indigenous if they
were Aboriginal and/or Torres Strait Islander in their
demographical data entry in the clinical records.
Abnormal liver function was defined by any rise in
liver transaminases and bilirubin. Neutropenia was
defined as a neutrophil count of <2.7  109/l and
thrombocytopenia as a platelet count of <150,000
platelets/ml. For the purpose of assessing safety, we also
defined categories of thrombocytopenia, based on the
protocol that we have developed with platelet counts
of <80,000, $80,000 to <150,000, and $150 000, and
based on the conventional definition of platelet counts
by severity of <50,000, $50,000 to <150,000,
and $150 000.Dosing of TrimethoprimþSulfamethoxazole
There were no guidelines for dosing of TMPþSMX for
prophylaxis of melioidosis in hemodialysis patients, so
we initially used the standard dosage that has been
safely used as eradication treatment for persons on a
dialysis dose of 1 double-strength tablet of TMPþSMX
160 mg/800 mg once a day.21 On dialysis days, the
patients received the drug after dialysis. All patients on
the prophylaxis also received folic acid 5 mg once a day
to avoid TMPþSMXinduced folate deficiency.Treatment Rollout
All 261 patients who were eligible and were not
receiving treatment for melioidosis were offered treat-
ment. The medication rollout was undertaken from 1
November 2014, with the last patient receiving the first
dose on 11 January 2015.Clinical Safety and Laboratory Monitoring
The majority of our patients receive hemodialysis
within satellite dialysis units at least 3 times a week,
achieving a minimum of 12 hours of treatment per
week,22 and have blood tests performed monthly (at
the start of every month or whenever clinically indi-
cated) as part of routine care. The renal pharmacist
provided in-services to primary dialysis nurses across
all dialysis units, who then routinely asked questions
of each patient pertaining to any medication compli-
cations. Patients were asked to report signs of nausea,
vomiting, and skin reactions at each dialysis session
and whenever they attended a nephrologist’s clinic
appointment. Patients concurrently were specifically
monitored for the development of neutropenia,
thrombocytopenia, and abnormal liver function at each
monthly blood test throughout the treatment phase and
for another 2 months after completion.162Statistical Analysis
A descriptive analysis was undertaken. Data are
described as frequency and percentage for categorical
variables, and continuous data were reported as mean
(SD) with 95% CIs for normally distributed data and as
median (interquartile range) for data that were not
normally distributed. For comparisons, we used a
2-sample Student t test for continuous normally
distributed data and the MannWhitney U test for
nonnormally distributed data. Comparisons between
categorical data were performed using the c2 and
Fisher exact tests as appropriate. Data were analyzed
using intention-to-treat analysis. Statistical significance
was determined by a 2-tailed P value of < 0.05 and
95% CIs where appropriate.
Treatment Cessation
The treatment was stopped in > 95% of patients on 30
April 2015. In the rest of the patients, treatment was
stopped within a few days after 30 April 2015.
Ethical Considerations
The Darwin Prospective Melioidosis Study is a pro-
spective study approved by the Human Research
Ethics Committee of the Northern Territory Depart-
ment of Health and the Menzies School of Health
Research (Approval # HREC 02/38).20
RESULTS
Baseline Characteristics and Risks of
Melioidosis
A total of 269 patients were receiving maintenance
hemodialysis on 1 November 2014. Eight patients (3%)
developed melioidosis and were already receiving
appropriate therapy prior to the commencement of the
prophylaxis intervention, and were thus excluded
from this analysis. These 8 patients received the
minimum 2-week intensive treatment with i.v. antibi-
otics (ceftazidime or meropenem), followed by the
3-month eradication therapy with TMPþSMX. They
then continued on prophylaxis (dose similar to that of
the eradication therapy) to the end of the wet season,
and were not included in the overall analysis (Figure 2).
The analysis describes the remaining 261 patients
(97%), divided into the TMPþSMX prophylaxis group
(who received prophylaxis, n ¼ 169 [64.8%]) and the
nonprophylaxis group (who did not receive prophy-
laxis, n ¼ 92 [35.2%]). Of the 92 patients who did not
receive the prophylaxis (92/262 [35.2%]), the reasons
were history of allergy to the drug (n ¼ 10), remoteness
and other logistical reasons (n ¼ 60), poor attendance
for dialysis (n ¼ 11), and refusal of treatment (n ¼ 11).
Overall, the main comorbidities included diabetes
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Figure 2. Melioidosis intervention study flow diagram.
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congestive cardiac failure, and rheumatic heart
disease), hypertension (66.7%), and chronic lung dis-
ease (36.8%). None of the 269 patients were on any
immunosuppressive therapy.
There was no significant difference in the age of
participants by group (TMPþSMX-prophylaxis group
vs. nonprophylaxis group, 54.7 [11.3] years vs. 54.3
[11.2] years; P ¼ 0.751). The proportion of indigenous
patients in each group was also similar atw 85% There
was no statistically significant difference in the baseline
platelet counts (180.8 [76.7], 95% CI ¼ 156.0205.7,Kidney International Reports (2018) 3, 160–167vs. 178.4 [75.2], 95% CI ¼ 154.0202.8, P ¼ 0.898) and
neutrophil counts (5.0 [2.2], 95% CI ¼ 4.25.7, vs. 5.9
[2.3], 95% CI ¼ 5.16.7, P ¼ 0.205) at the start of the
study between the groups. Table 1 provides the details
of the comparison in the baseline characteristics and
the risks of melioidosis between the 2 groups.
Adherence to Treatment
Of the 169 patients who received the treatment, 159
patients (94%) received the full treatment through the
study period. Of the remaining 10 patients (5.9%), 7
patients (4.1%) received treatment at least 2 times a week163
Table 1. Comparison of baseline characteristics and risk factors for








n (%) P value
Gender (male) 94 (55.6) 52 (56.5) 0.897
Ethnicity (indigenous) 143 (84.6) 78 (84.7) 1.000
Diabetes mellitus 113 (66.9) 61 (66.3) 0.728
Ischemic heart disease/heart failure 119 (70.4) 65 (70.7) 0.840
Chronic obstructive pulmonary disease 62 (36.7) 34 (37.0) 0.635
Chronic liver disease 6 (3.6) 4 (4.3) 0.670
Atrial fibrillation 104 (61.5) 56 (60.9) 0.648
Dyslipidemia 118 (69.8) 66 (71.7) 0.216
Hypertension 114 (67.5) 63 (68.5) 0.917
Thyroid disease 7 (4.1) 4 (4.3) 1.000
History of latent tuberculosis 5 (3.0) 3 (3.3) 0.157
Obesity 8 (4.7) 5 (5.4) 0.517
Pulmonary hypertension 6 (3.6) 4 (4.3) 0.768
Rheumatic heart disease 11 (6.5) 9 (9.7) 0.547
Systematic lupus erythematosus 4 (2.4) 2 (2.2) 0.270
Secondary hyperparathyroidism 12 (7.1) 8 (8.7) 0.768
Dialysis adequacy
KT/V > 1.4 150 (88.8) 82 (89.1) 0.675
URR > 70 152 (90.0) 81 (88.0) 0.586
URR, urea reduction ratio.
CLINICAL RESEARCH SW Majoni et al.: Reducing Melioidosis Rates in High-Risk Dialysis Patientsmainly due to missing some dialysis sessions, and 3
patients (1.8%) stopped the treatment due to adverse drug
reactions.Table 2. Comparison between the 2 groups of the proportion of
patients in the categories with platelet count of 50,000/ml as the





P valuecProphylaxis n (%) Nonprophylaxis n (%)
1 1 2 (1.0) 2 (2.2) 0.613
2 72 (42.8) 19 (20.6)
3 95 (56.2) 71 (77.2)
2 1 2 (1.2) 2 (2.2) 0.613Efficacy of TMPþSMX Prophylaxis and Cases of
Melioidosis
During the period from 1 November 2014 to 30 April
2015, a total of 16 documented cases of culture-positive
melioidosis (6%) were observed among the 261 hemo-
dialysis patients eligible for this analysis. This corre-
sponds to a melioidosis event frequency of 0% in the
TMPþSMX prophylaxis group and 17.4%in the
nonprophylaxis group (0/169 vs. 16/92, P < 0.001).2 69 (40.8) 16 (17.4)
3 98 (58.0) 74 (80.4)
3 1 4 (2.4) 2 (2.2) 1.000
2 68 (40.2) 15 (16.3)
3 97 (57.4) 74 (81.5)
4 1 3 (1.8) 2 (2.2) 1.000
2 67 (40.2) 14 (16.3)
3 97 (58.0) 72 (81.5)
5 1 3 (1.8) 1 (1.1) 1.000
2 54 (33.1) 19 (21.7)
3 107 (65.1) 66 (77.2)
6d 1 4 (2.4) 1 (1.1) 0.660
2 49 (30.2) 15 (17.4)
3 110 (67.5) 69 (81.5)
aMonth after start of treatment.
bPlatelet count categories (per ml): 1: # 50,000; 2: 51,000150,000; 3: $150,000.
cFisher exact test.
dOne month after stopping treatment.
There was no statistically significant difference in platelet counts at baseline between
the 2 groups.Mortality
Thirteen patients (5%) died during the 6-month period
of the treatment. Six of 169 patients (3.6%) were from
the TMPþSMX prophylaxis group, and 7 of 92 patients
(7.6%) were from the nonprophylaxis group
(P ¼ 0.231). One patient among the 8 patients who
were receiving treatment for melioidosis at the time of
starting the study died of complications related to a
myocardial infarction but had completely recovered
from the infection at the time of death. The 6 patients
in the TMPþSMX prophylaxis group died of compli-
cations related to cardiovascular disease.
In the nonprophylaxis group, 4 of the 7 patients
died of melioidosis, and the other 3 patients died of
cardiovascular complications. The remaining 12164patients who had melioidosis (75%) were successfully
treated as per protocol.16,17Safety of the Trimethoprim/Sulfamethoxazole
Prophylaxis
There was a higher incidence rate of nonclinically
significant thrombocytopenia noted in the TMPþSMX-
prophylaxis group (Tables 2 and 3); however, the
majority of cases were not severe enough to warrant
the withdrawal of treatment. Three patients (1.8%)
were withdrawn from the TMPþSMX-prophylaxis
group due to significant side effects. These patients
included 1 patient with drug reaction with eosinophilia
and systemic symptoms syndrome (DRESS) and
thrombocytopenia and 2 patients with skin rash.
One patient had a severe skin reaction, which
improved after stopping the TMPþSMX. The
second patient in the TMPþSMX prophylaxis
group who developed DRESS also had multiorganism
culturepositive severe sepsis. She was on peritoneal
dialysis (PD) and developed severe PD peritonitis
requiring PD catheter removal. She was converted to
hemodialysis as a bridging treatment pending complete
recovery from the PD peritonitis. She had a short
period dialysing via a temporary internal jugular
catheter. Upon complete recovery from the infections,
the catheter was converted to a tunneled catheter. SheKidney International Reports (2018) 3, 160–167
Table 3. Comparison between the 2 groups of the proportion of
patients in categories with platelet count of 80,000/ml as the
minimum during the study and 1 month after stopping treatment
Montha Platelet count categoryb
Group
P valuecProphylaxis n (%) Nonprophylaxis n (%)
1 1 10 (5.9) 5 (5.4) 1.000
2 64 (37.9) 16 (17.2)
3 95 (56.2) 71 (77.2)
2 1 14 (8.3) 4 (4.4) 0.309
2 57 (33.7) 14 (15.2)
3 98 (58.0) 74 (80.4)
3 1 14 (8.3) 3 (3.3) 0.187
2 58 (34.3) 14 (15.2)
3 97 (57.4) 74 (81.5)
4 1 13 (7.7) 3 (3.3) 0.185
2 57 (34.3) 13 (15.2)
3 97 (58.0) 72 (81.5)
5 1 13 (8.3) 4 (4.3) 0.309
2 44 (26.6) 16 (18.5)
3 107 (65.1) 66 (77.2)
6d 1 10 (5.9) 4 (4.4) 0.776
2 43 (26.6) 12 (14.1)
3 110 (67.5) 69 (81.5)
aMonth after start of treatment.
bPlatelet count categories (per ml): 1: #80,000; 2: 81,000150 000; 3: $150,000.
cFisher exact test.
dOne month after stopping treatment.
There was no statistically significant difference in platelet counts at baseline between
the 2 groups.
Table 4. Comparison between the 2 groups of the proportion of











1 1 15 (8.9) 2 (2.2) 0.038
2 154 (91.1) 90 (97.8)
2 1 14 (8.3) 5 (5.4) 0.464
2 155 (91.7) 87 (94.6)
3 1 15 (8.9) 2 (2.2) 0.038
2 154 (91.1) 89 (97.8)
4 1 15 (9.0) 2 (2.2) 0.039
2 152 (91.0) 86 (97.8)
5 1 18 (11.2) 3 (3.3) 0.009
2 146 (88.8) 83 (96.7)
6d 1 13 (7.7) 3 (3.3) 0.185
2 150 (92.3) 82 (96.7)
aMonths from start of treatment.
bNeutrophil count categories ( 109/l): 1: < 2.7; 2: $ 2.7.
cFisher exact test.
dOne month after stopping treatment.
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for melioidosis. Four weeks later, she was admitted
with a presumed infection of the right-sided internal
jugular vein tunneled dialysis catheter and a skin rash.
She was commenced on several antibiotics including
vancomycin, meropenem, and fluconazole, as blood
cultures were positive for multiple organisms which
included Pseudomonas eruginosa, Staphylococcus capitis,
Staphylococcus epidermidis, and Candida species. The
TMPþSMX was immediately stopped on admission due
to the rash, but the patient continued to deteriorate and
subsequently died. The cause of death in this patient
was attributed to a combination of sepsis with severe
drug reaction. It was not possible to exclude other
antibiotics as the cause of DRESS. Nevertheless, the
temporal relationship between the initial appearance of
the rash prior to commencement of the other antibiotics
suggested that TMPþSMX was the most likely cause.
Neutropenia was more common in the TMPþSMX
prophylaxis group than the nonprophylaxis group.
However, this was generally not severe enough to cease
the prophylaxis in any patient (Table 4).
There was no difference in abnormal liver function
between the 2 groups. There was no impact on hemo-
globin and requirements for erythropoiesis-stimulating
agents. Thrombocytopenia and neutropenia had
improved in all patients in the 2 months after ceasing
the prophylaxis.Kidney International Reports (2018) 3, 160–167Figure 2 shows a flow diagram of how patients were
evaluated, by TMPþSMX prophylaxis group and
nonprophylaxis group, and presentation of selected
events.DISCUSSION
We completed a prospective interventional study to
determine the safety and efficacy of daily oral
TMPþSMX prophylaxis to prevent melioidosis among
a cohort of maintenance hemodialysis patients living in
a region with endemic Burkholderia pseudomallei and
melioidosis-related harms. The key findings are as fol-
lows: (i) daily oral TMPþSMX prophylaxis was prob-
ably efficacious against melioidosis in hemodialysis
patients; (ii) daily dosing was relatively safe, although
there was a tendency for increased episodes of
nonsevere thrombocytopenia and neutropenia, without
hepatic adverse events; (iii) logistical difficulties with
administration of a daily dosing regimen and patient
factors resulted in a number of patients being excluded
from the prophylaxis; and (iv) the incidence rate of
melioidosis of 17.4% in the nonprophylaxis group was
higher than in our recent publication11; however, this
is not unusual, as it has been shown in previous work
in which rates as high as 29% have been recorded
during some wet seasons12,23 (Figure 1).
The predominant reason for some patients not
receiving prophylaxis was remoteness and logistical
reasons. Our dialysis patients from remote areas
perform self-care dialysis and dialysis in remote satel-
lite units. By selection, they tend to be the healthiest
patients, who can manage self-care and require minimal
support. They receive regular follow-up by their165
CLINICAL RESEARCH SW Majoni et al.: Reducing Melioidosis Rates in High-Risk Dialysis Patientsnephrologists. However, these logistical issues have
been addressed in the subsequent wet seasons, and
patients now receive the prophylaxis regardless of
where they have dialysis.
In this high-risk population,11 the prophylaxis
intervention was effective when provided in combi-
nation with wet season personal preventive advice,20
as no cases of melioidosis were observed in the
TMPþSMX prophylaxis group. These measures
include minimizing contact with the bacteria
(covering open skin wounds, avoiding contact with
soil and standing water, and wearing covered foot-
wear) and using standard contact precautions (mask,
gloves, and gown where appropriate) to help prevent
infection.14
All cases of melioidosis occurred in patients who
either developed the infection before the prophylaxis
was introduced, or did not receive the prophylaxis,
which supports the policy in our region of routinely
providing melioidosis prophylaxis during the wet
season. The nonprophylaxis group included patients
who had nonmodifiable reasons (including TMPþSMX
allergy, the frequency of which was similar to that in
other reports of TMPþSMX),24 and reasons that may be
modifiable. Potentially modifiable causes of ineligibility
for the prophylaxis group included client preferences
to decline a prophylactic treatment, and timely supply
of the drug to home-based patients in regions remote
from the treatment center.
Thrombocytopenia and neutropenia among partici-
pants in the TMPþSMX-group were observed
(Tables 2–4), but were not severe enough to warrant
withdrawal of treatment. It is important to note that a
number of patients in the sample had low platelet and
neutrophil counts that were not related to the
TMPþSMX, as evidenced by rates of thrombocyto-
penia and neutropenia in the nonprophylaxis group
(Tables 2–4). Withdrawal of TMPþSMX was required
only in the event of a severe drug reaction.
Our data show the safe and efficacious use of
TMPþSMX to mitigate melioidosis in our hemodialysis
cohort, which has been developed into a comprehen-
sive protocol for the next wet season (20152016)
(Supplementary Material S1). To address logistic sup-
ply issues and pill burden and to improve medication
adherence, we adapted the prophylaxis intervention,
using TMPþSMX 1 double-strength tablet supervised
post-dialysis 3 times a week in the wet season from 1
November 2015 to 30 April 2016. There were no
identified cases of melioidosis during this period in
those on the 3 times a week prophylaxis, and there
were no significant adverse events. Following the
success of this treatment, a comprehensive educational
and awareness program led by the Northern Territory166Centre for Disease Control has been undertaken to in-
crease staff and patient education and awareness. We
have produced a patient information video25 and are
addressing medication prescribing and dispensing and
monitoring issues. In the current incomplete wet sea-
son (1 November 2016 to 30 April 2017), there have
been 3 cases of melioidosis in patients who had not
started the prophylaxis due to various logistic issues.
To date, we have not yet implemented a prophylaxis
program for our peritoneal dialysis cohort, as antibiotic
use can be linked to the development of fungal
peritonitis.
A number of limitations of this study are
acknowledged. It is a prospective observational study
of an antibiotic intervention that required voluntary
participation, which introduces the potential for bias.
However, the study has clearly shown efficacy and
safety of the administration of TMPþSMX in hemo-
dialysis patients. There have been no events to date of
TMPþSMX-resistant melioidosis in this cohort, but
careful monitoring is required to ensure ongoing
surveillance and drug stewardship. This prophylaxis
program has been successful as part of a comprehen-
sive multiagency strategy to mitigate harm in our
patients. Patients within our hemodialysis cohort are
regularly engaged in clinical care, which enables a
greater responsiveness to side effects or adverse
events. It is unknown whether this protocol may be
effective in groups with less access to health care and
monitoring, such as the wider diabetic population
in melioidosis-endemic regions. Finally, potential
confounding factors, especially the adherence to pre-
ventive measures for melioidosis, were not adjusted for
in the study, although we have no reason to believe
that this was different between the 2 groups.
In conclusion, the use of 1 double-strength tablet of
TMPþSMX postdialysis in hemodialysis patients was
shown to be effective and safe in the prevention of
melioidosis. We recommend the use of this approach in
tropical Northern Australia and other regions where
melioidosis is prevalent.DISCLOSURE
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